Mesfin Yimam, Young-Chul Lee, Tae-Woo Kim, Breanna Moor,Ping Jiao, Mei Hong, Hyun-Jin Kim, Jeong-Bum Nam, Mi-Ran Kim, Jin-Sun Oh, Sabrina Clevel and, Eu-Jin Hyun, Min Chu,and Qi Jia
Osteoarthritis (OA) is a multifactorial disease primarily noted by cartilage degradation in association with inflammation that causes significant morbidity, joint pain, stiffness, and limited mobility. Present-day management of OA is inadequate due to the lack of principal therapies proven to be effective in hindering disease progression where symptomatic therapy focused approach masks the actual etiology leading to irreversible damage. Here, we describe the effect of UP3005, a composition containing a proprietary blend of two standardized extracts from the leaf of Uncaria gambir and the root bark of Morus alba, in maintaining joint structural integrity and alleviating OA associated symptoms in monosodium-iodoacetate- (MIA-) induced rat OA disease model. Pain sensitivity, micro-CT, histopathology, and glycosaminoglycans (GAGs) level analysis were conducted. Diclofenac at 10 μg/kg was used as a reference compound. UP3005 resulted in almost a complete inhibition in proteoglycans degradation, reductions of 16.6% (week 4), 40.5% (week 5), and 22.0% (week 6) in
mulberroside A was purchased from Chengdu Biopurify Phytochemicals (Catalog number: BP0964).
